Hughes T P, Ambrosetti A, Barbu V, Bartram C, Battista R, Biondi A, Chiamenti A, Cimino G, Ernst P, Frassoni F
MRC/LRF Leukaemia Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Leukemia. 1991 Jun;5(6):448-51.
The proceedings of the third workshop of the molecular biology/bone marrow transplantation (BMT) study group held in January 1991 in Verona, Italy. This workshop was convened to review progress in the application of molecular techniques to the diagnosis and follow-up of patients with chronic myeloid leukaemia (CML) as well as other haematologic malignancies. The results of polymerase chainreaction studies in 157 CML patients 1-90 months post BMT suggest that leukaemia is frequently detectable for the first 12 months but rarely detected thereafter except in patients known to have a high risk of relapse. In the acute leukaemias and lymphomas there is a rapidly increasing number of leukaemia-specific as well as clone-specific molecular markers now available for the detection of minimal disease. It may be possible to coordinate multi-center prospective studies to investigate the role of these markers in the diagnosis and follow-up of haematologic malignancies.
1991年1月在意大利维罗纳举行的分子生物学/骨髓移植（BMT）研究小组第三次研讨会会议记录。本次研讨会旨在回顾分子技术在慢性粒细胞白血病（CML）以及其他血液系统恶性肿瘤患者诊断和随访中的应用进展。对157例骨髓移植后1至90个月的慢性粒细胞白血病患者进行聚合酶链反应研究的结果表明，白血病在最初12个月内经常可检测到，但此后很少检测到，已知复发风险高的患者除外。在急性白血病和淋巴瘤中，现在有越来越多的白血病特异性以及克隆特异性分子标志物可用于检测微小疾病。有可能协调多中心前瞻性研究，以调查这些标志物在血液系统恶性肿瘤诊断和随访中的作用。
